Lundberg I E
Department of Rheumatology, Karolinska Hospital, S-171 76 Stockholm, Sweden.
Curr Rheumatol Rep. 2000 Jun;2(3):216-24. doi: 10.1007/s11926-000-0082-y.
Cytokines, chemokines, and adhesion molecules are important mediators in chronic inflammation and in immune regulation. In idiopathic inflammatory myopathies (IIM), increased expression of proinflammatory cytokines particularly interleukin (IL)-1alpha and IL-1beta, tumor necrosis factor (TNF)-alpha and macrophage inflammatory proteins (MIP)-1alpha, as well as of the inhibitory cytokines transforming growth factor (TGF)-beta was observed in muscle. There was no difference in cytokine and chemokine pattern between polymyositis, dermatomyositis, and inclusion body myositis, which could indicate that similar pathogenetic mechanisms are involved in these subsets of myositis. A prominent finding of IL-1alpha expression in endothelial cells, both in patients with active inflammation and in patients with chronic persisting muscle weakness without inflammation, makes this an interesting molecule in understanding the mechanisms for the pathogenesis of muscle weakness. Involvement of the blood vessels in the pathogenesis of myositis was further supported by increased expression of adhesion molecules and by a phenotypical expression of endothelial cells, resembling high endothelium venules in all three subsets of IIM. The molecular studies to date indicate a role of the microvessels in the pathogenesis of IIM not only in DM, as was previously suggested, but also in PM and IBM. The studies also indicate that IL-1alpha could be a target molecule for new therapeutical interventions.
细胞因子、趋化因子和黏附分子是慢性炎症和免疫调节中的重要介质。在特发性炎性肌病(IIM)中,肌肉中促炎细胞因子尤其是白细胞介素(IL)-1α和IL-1β、肿瘤坏死因子(TNF)-α以及巨噬细胞炎性蛋白(MIP)-1α的表达增加,同时抑制性细胞因子转化生长因子(TGF)-β的表达也增加。多发性肌炎、皮肌炎和包涵体肌炎之间的细胞因子和趋化因子模式没有差异,这可能表明这些肌炎亚组涉及相似的发病机制。在有活动性炎症的患者以及无炎症的慢性持续性肌肉无力患者的内皮细胞中,IL-1α表达显著,这使得它成为理解肌肉无力发病机制的一个有趣分子。黏附分子表达增加以及内皮细胞的表型表达类似于IIM所有三个亚组中的高内皮微静脉,进一步支持了血管参与肌炎发病机制的观点。迄今为止的分子研究表明,微血管不仅如先前所提示的那样在皮肌炎的IIM发病机制中起作用,而且在多发性肌炎和包涵体肌炎中也起作用。这些研究还表明,IL-1α可能是新治疗干预的靶分子。